{"id":3190,"date":"2024-06-10T11:22:33","date_gmt":"2024-06-10T15:22:33","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/"},"modified":"2024-08-22T05:34:32","modified_gmt":"2024-08-22T09:34:32","slug":"how-and-why-to-implement-optimal-adaptive-promising-zone-designs","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/","title":{"rendered":"How and Why to Implement Optimal Adaptive Promising Zone Designs"},"content":{"rendered":"<p>When determining the best possible statistical design for a particular trial, large pharmaceuticals and small biotechs benefit from different quantitative strategies. A new line of study from Cytel statisticians, with colleagues at Harvard University, Bristol Meyers Squibb, and Vertex Pharmaceuticals, reveals the tactical advantages of different approaches to sample size re-estimation. Using the familiar promising zone design, <a href=\"https:\/\/cytel.agencyukdev.com\/fr\/employee\/cyrus-mehta\/\">Cyrus Mehta<\/a>, Pralay Senchaudhuri, Apurva Bhingare and Lingyun Liu demonstrate how to optimize for power, bearing in mind considerations like resource constraints and commercial goals.<\/p>\n<p><!--more--><\/p>\n<p><strong>What are Promising Zone Designs?<\/strong><\/p>\n<p>Promising zone designs refer to methods of adaptive sample size re-estimation, which enable sponsors to increase sample size based on whether the data gathered at an interim look is promising. The design enables statisticians to examine the interim data of an on-going trial and make an estimate as to whether the trial will be sufficiently powered if allowed to continue. A decision can then be made to either stop for futility, stop for overwhelming efficacy, or if deemed promising, can extend the sample size to secure more power.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>How to Use Conditional and Unconditional Power Tactically:<\/strong><\/p>\n<p>There are at least two ways to predict the power of a clinical trial during the interim look.<\/p>\n<ul>\n<li>Unconditional Power: Unconditional power is calculated by using the existing data to forecast the outcome for a large number of hypothetical future clinical trials similar to the present one , and then calculating the average success rate across those trials.<\/li>\n<li>Conditional Power: Conditional power is calculated by using existing data to forecast whether or not the current trial will be sufficiently powered at the point of completion. Conditional power has a Bayesian analogue in predictive power.<\/li>\n<\/ul>\n<p>Pharmaceutical companies with dozens of clinical trials in their portfolio are positioned to use unconditional power measures, since over the course of several trials the average success rate should equal the desired unconditional power. By contrast, biotechs pursuing a trial for a single asset, might value conditional power as a clearer guide on how to distribute clinical trial resources.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Which treatment effect assumptions should we use?<\/strong><\/p>\n<p>When designing clinical trials with sample size re-estimation, it is usually the case that sponsors assume a realistic (or often optimistic) treatment effect. Yet clearly there is value to knowing whether a sample size increase will facilitate detection of a smaller treatment effect that is both a clinically meaningful and economically viable. Mehta, et al., demonstrate that increasing the sample size to detect a pessimistic treatment effect can add tactical value to a design even though it comes at a cost to sacrificing a small amount of unconditional power. They propose two different sample size re-estimation rules (frequentist and Bayesian) that guarantee sufficient power to detect clinically meaningful treatment effects if the interim results are promising.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p>We develop optimal decision rules for sample size re-estimation in two-stage adaptive group sequential clinical trials. It is usual for the initial sample size specification of such trials to be adequate to detect a realistic treatment effect \u03b4 a with good power, but not sufficient to detect the smallest clinically meaningful treatment effect \u03b4 min . Moreover it is difficult for the sponsors of such trials to make the up-front commitment needed to adequately power a study to detect \u03b4 min . It is easier to justify increasing the sample size if the interim data enter a so-called \u201cpromising zone\u201d that ensures with high probability that the trial will succeed. We have considered promising zone designs that optimize unconditional power and promising zone designs that optimize conditional power and have discussed the tension that exists between these two objectives. Where there is reluctance to base the sample size re-estimation rule on the parameter \u03b4 min we propose a Bayesian option whereby a prior distribution is assigned to the unknown treatment effect \u03b4, which is then integrated out of the objective function with respect to its posterior distribution at the interim analysis.<\/p>\n<div>\n<p>&nbsp;<\/p>\n<\/div>","protected":false},"featured_media":3470,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[76],"by-topic":[429],"by-year":[72],"class_list":["post-3190","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry","tag-blog","by-topic-adaptive-clinical-trials","by-year-72"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>How and Why to Implement Optimal Adaptive Promising Zone Designs - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us<\/title>\n<meta name=\"description\" content=\"A new study from Cytel statisticians and colleagues reveals the tactical advantages of different approaches to sample size re-estimation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How and Why to Implement Optimal Adaptive Promising Zone Designs - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"og:description\" content=\"A new study from Cytel statisticians and colleagues reveals the tactical advantages of different approaches to sample size re-estimation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-22T09:34:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\\\/\",\"url\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\\\/\",\"name\":\"How and Why to Implement Optimal Adaptive Promising Zone Designs - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-06.jpg\",\"datePublished\":\"2024-06-10T15:22:33+00:00\",\"dateModified\":\"2024-08-22T09:34:32+00:00\",\"description\":\"A new study from Cytel statisticians and colleagues reveals the tactical advantages of different approaches to sample size re-estimation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-06.jpg\",\"contentUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-06.jpg\",\"width\":2048,\"height\":1365},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How and Why to Implement Optimal Adaptive Promising Zone Designs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\",\"name\":\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"description\":\"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How and Why to Implement Optimal Adaptive Promising Zone Designs - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"A new study from Cytel statisticians and colleagues reveals the tactical advantages of different approaches to sample size re-estimation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/","og_locale":"fr_FR","og_type":"article","og_title":"How and Why to Implement Optimal Adaptive Promising Zone Designs - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","og_description":"A new study from Cytel statisticians and colleagues reveals the tactical advantages of different approaches to sample size re-estimation.","og_url":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/","og_site_name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","article_modified_time":"2024-08-22T09:34:32+00:00","og_image":[{"width":2048,"height":1365,"url":"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/","url":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/","name":"How and Why to Implement Optimal Adaptive Promising Zone Designs - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","isPartOf":{"@id":"https:\/\/cytel.agencyukdev.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/#primaryimage"},"image":{"@id":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/#primaryimage"},"thumbnailUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg","datePublished":"2024-06-10T15:22:33+00:00","dateModified":"2024-08-22T09:34:32+00:00","description":"A new study from Cytel statisticians and colleagues reveals the tactical advantages of different approaches to sample size re-estimation.","breadcrumb":{"@id":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/#primaryimage","url":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg","contentUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg","width":2048,"height":1365},{"@type":"BreadcrumbList","@id":"https:\/\/www.cytel.com\/perspectives\/how-and-why-to-implement-optimal-adaptive-promising-zone-designs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cytel.agencyukdev.com\/"},{"@type":"ListItem","position":2,"name":"How and Why to Implement Optimal Adaptive Promising Zone Designs"}]},{"@type":"WebSite","@id":"https:\/\/cytel.agencyukdev.com\/#website","url":"https:\/\/cytel.agencyukdev.com\/","name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cytel.agencyukdev.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives\/3190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media\/3470"}],"wp:attachment":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media?parent=3190"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/tags?post=3190"},{"taxonomy":"by-topic","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-topic?post=3190"},{"taxonomy":"by-year","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-year?post=3190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}